1-5 of 5
Jane Apperley, FRCP, FRCPath, MB
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Andreas Hochhaus, MD, Carla Boquimpani, MD, Delphine Rea, MDPhD, Yosuke Minami, MDPhD, Elza Lomaia, MD PhD, Sergey Voloshin, MD PhD, Anna G. Turkina, Prof., MD, Dong-Wook Kim, MD, Jane Apperley, FRCP, FRCPath, MB, Jorge E. Cortes, MD, Andre Abdo, MD, Laura Maria Fogliatto, MD PhD, Dennis Dong Hwan Kim, MD PhD, Philipp D le Coutre, MD, Susanne Saussele, MD, Mario Annunziata, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Naeem A. Chaudhri, MD, Lynette C.Y. Chee, MBBS,PhDFRACP,FRCPA, Valentín García Gutiérrez, MD PhD, Koji Sasaki, MD, Paola Aimone, MD, Alex Allepuz, MD MPH, Sarah Quenet, Véronique Bédoucha, Michael J. Mauro, MD
Journal: Blood
Blood (2020) 136 (Supplement_2): LBA-4.
https://doi.org/10.1182/blood-2020-143816
Published: 2020
Journal Articles

Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia

Simone Claudiani, Carolina Rosadas, Myra McClure, Maryam Khan, Richard S. Tedder, Andrew J. Innes, Dragana Milojkovic, Jane Apperley, FRCP, FRCPath, MB
Journal: Blood
Blood (2020) 136 (Supplement 1): 20.
https://doi.org/10.1182/blood-2020-142454
Published: 2020
Journal Articles

Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML

Jorge E. Cortes, MD, Jane Apperley, FRCP, FRCPath, MB, Andreas Hochhaus, MD, Michael J. Mauro, MD, Philippe Rousselot, MDPhD, Tomasz Sacha, MDPhD, Moshe Talpaz, MD, Charles Chuah, MD, Jeffrey H. Lipton, MD PhD, Michael W. Deininger, MD PhD, Charles A. Schiffer, MD, Lori J. Maness, MD, James K. McCloskey, MD, Valentín García Gutiérrez, MD PhD, Hugues de Lavallade, MD PhD, Gabriel Etienne, MD PhD, Vickie Lu, PhD, Shouryadeep Srivastava, MBBS, PhD, Gianantonio Rosti, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-135883
Published: 2020
Journal Articles

Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic

Hagop M. Kantarjian, MD, Michael W. Deininger, MD PhD, Elisabetta Abruzzese, MD, Jane Apperley, FRCP, FRCPath, MB, Jorge E. Cortes, MD, Charles Chuah, MD, Daniel J. DeAngelo, MD PhD, John F. DiPersio, MD PhD, Andreas Hochhaus, MD, Jeffrey H. Lipton, MD PhD, Franck E Nicolini, MDPhD, Javier Pinilla Ibarz, MD PhD, Delphine Rea, MDPhD, Gianantonio Rosti, MD, Philippe Rousselot, MDPhD, Neil P Shah, MD PhD, Moshe Talpaz, MD, Shouryadeep Srivastava, MBBS, PhD, Vickie Lu, PhD, Michael J. Mauro, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-133922
Published: 2020
Journal Articles

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Jorge E. Cortes, MD, Tapan Saikia, MD, Dong-Wook Kim, MD, Yesid Alvarado, MD, Franck E Nicolini, MDPhD, Navin Khattry, MD DM, Krishnakumar Rathnam, MD DM, Jane Apperley, FRCP, FRCPath, MB, Michael W. Deininger, MD PhD, Hugues de Lavallade, MD PhD, Aude Charbonnier, MD PhD, Nikki Granacher, MD, Carlo Gambacorti-Passerini, MD, Alessandro Lucchesi, MD, Michael J. Mauro, MD, Gregor Verhoef, MD PhD, Peter Vandenberghe, MD, Andrew R. Whiteley, MD, Shashikant Apte, MD FRCPA, Siu-Long Yao, MD, Mudgal Kothekar, MD, Jayasree Sreenivasan, MSc, Bimba HV, MD, Geetanjali Chimote, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 51–52.
https://doi.org/10.1182/blood-2020-139847
Published: 2020